Comparative Pharmacology
Head-to-head clinical analysis: CYCLESSA versus JUNEL 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLESSA versus JUNEL 1 5 30.
CYCLESSA vs JUNEL 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via estrogen and progestin negative feedback, inhibiting ovulation. Changes cervical mucus viscosity and endometrial lining to impede sperm penetration and implantation.
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily.
None Documented
None Documented
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
EE: terminal half-life ~17 ± 8 hours; NET: terminal half-life ~8 ± 1 hours. Steady-state achieved within ~2-3 cycles.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Ethinyl estradiol (EE) and norethindrone (NET) are excreted in urine (40-60% as metabolites) and feces (20-30% as metabolites). NET is also excreted in bile and undergoes enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive